Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib

被引：0
作者：
Kazuo Tamura
Toshihiro Nukiwa
Akihiko Gemma
Nobuyuki Yamamoto
Masaya Mizushima
Kaori Ochai
Rie Ikeda
Hisaya Azuma
Yoichi Nakanishi
机构：
[1] Fukuoka University,General Medical Research Center, School of Medicine
[2] Tohoku University,Division of Pulmonology and Medical Oncology, Third Department of Internal Medicine
[3] Nippon Medical School,Speciality Care Medicine, Medical Division
[4] Wakayama Medical University,PMS Division, Statistics Analysis Department 2
[5] Nippon Boehringer Ingelheim Co.,Post Marketing Surveillance Group, Pharmacovigilance
[6] Ltd.,Research Institute for Diseases of the Chest, Graduate School of Medical Sciences
[7] EPS Corporation,undefined
[8] Nippon Boehringer Ingelheim Co.,undefined
[9] Ltd.,undefined
[10] Kyusyu University,undefined
来源：
International Journal of Clinical Oncology | 2019年 / 24卷
关键词：
Afatinib; m + NSCLC; Japanese patients; Real-world data; Post-marketing observational study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：917 / 926
页数：9
相关论文
共 48 条
  • [1] Zhang YL(2016)The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis Oncotarget 7 78985-78993
  • [2] Yuan JQ(2012)Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker J Pharmacol Exp Ther 343 342-350
  • [3] Wang KF(2013)Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations J Clin Oncol 31 3327-3334
  • [4] Solca F(2014)Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial Lancet Oncol 15 213-222
  • [5] Dahl G(2015)Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials Lancet Oncol 16 141-151
  • [6] Zoephel A(2015)Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: subgroup analysis of LUX-Lung 3 Cancer Sci 106 1202-1211
  • [7] Sequist LV(2012)Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR) J Thorac Oncol 7 1296-1303
  • [8] Yang JC(2013)Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405) Jpn J Clin Oncol 43 664-668
  • [9] Yamamoto N(2014)Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials Lung Cancer 83 231-239
  • [10] Wu YL(2010)Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience J Thorac Oncol 5 179-184
12345